ABIO - ARCA biopharma, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.0800
-0.0300 (-1.42%)
At close: 04:00PM EDT
2.0300 -0.05 (-2.40%)
After hours: 06:40PM EDT
Stock chart is not supported by your current browser
Previous Close2.1100
Open2.0500
Bid2.0400 x 900
Ask2.1100 x 1300
Day's Range2.0300 - 2.1100
52 Week Range1.8500 - 2.7000
Volume12,818
Avg. Volume25,639
Market Cap29.973M
Beta (5Y Monthly)1.37
PE Ratio (TTM)N/A
EPS (TTM)-0.5500
Earnings DateJul 31, 2023 - Aug 04, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    ARCA biopharma Announces First Quarter 2023 Financial Results

    Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic optionsWESTMINSTER, Colo., April 24, 2023 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2023 financial results and provided a corporate update. In April 2022, the Board of Dir

  • GlobeNewswire

    ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update

    Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic optionsWESTMINSTER, Colo., Feb. 24, 2023 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported 2022 financial results and provided a corporate update. In May 2022, the Company retained Ladenburg Th

  • Simply Wall St.

    Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation

    We can readily understand why investors are attracted to unprofitable companies. For example, although...

  • GlobeNewswire

    James Flynn Joins ARCA biopharma Board of Directors

    WESTMINSTER, Colo., Dec. 19, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that James Flynn has joined its Board of Directors. “We are pleased to welcome James Flynn to our Board,” said Robert E. Conway, Chairman of ARCA’s Board of Directors. “We appreciate his participation and input on the Company’s Board of Directors, including our process for evaluating strategic options for the Company.” Mr. Flynn is currently a Managing Member and Portfolio Manager of Nerium

  • Simply Wall St.

    One ARCA biopharma, Inc. (NASDAQ:ABIO) insider upped their stake by 5,155% in the previous year

    Viewing insider transactions for ARCA biopharma, Inc.'s ( NASDAQ:ABIO ) over the last year, we see that insiders were...

  • GlobeNewswire

    ARCA biopharma Announces Third Quarter 2022 Financial Results

    Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic optionsWESTMINSTER, Colo., Oct. 28, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported third quarter 2022 financial results and provided a corporate update. In May 2022, the Company retaine

  • GlobeNewswire

    ARCA biopharma Announces Second Quarter 2022 Financial Results

    Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2022 financial results and provided a corporate update. Dr. Michael Bristow, ARCA’s Pr

  • Simply Wall St.

    Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

  • GlobeNewswire

    Jacob Ma-Weaver Joins ARCA biopharma Board of Directors

    WESTMINSTER, Colo., June 21, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that Jacob Ma-Weaver has joined its Board of Directors. “We are pleased to welcome Jacob Ma-Weaver, the managing member of ARCA’s largest shareholder, to our Board,” said Robert E. Conway, Chairman of ARCA’s Board of Directors. “We appreciate his participation and input as we explore and evaluate strategic options for maximizing stockholder value.” Mr. Ma-Weaver is the Managing Member of Cab